ボルテゾミブの世界市場

ボルテゾミブの世界市場は2030年までに2,840万米ドルに達する見込み

2024年に2,390万米ドルと推定されるボルテゾミブの世界市場は、2030年には2,840万米ドルに達し、分析期間2024-2030年のCAGRは2.9%で成長すると予測されます。ボルテゾミブ注射は、本レポートで分析したセグメントの1つであり、CAGRは2.2％を記録し、分析期間終了時には1,830万米ドルに達すると予測されています。ボルテゾミブ Powder for Injection（注射用粉末）セグメントの成長率は、分析期間中CAGR 4.2％と推定されます。

米国市場は650万米ドルと推定、中国はCAGR 5.4％で成長予測

米国のボルテゾミブ市場は2024年に650万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに550万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2％と2.2％と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界のボルテゾミブ市場- 主要動向と促進要因のまとめ

ボルテゾミブが血液悪性腫瘍治療の要となる理由

ファースト・イン・クラスのプロテアソーム阻害剤であるボルテゾミブは、多発性骨髄腫およびマントル細胞リンパ腫（MCL）の治療において、依然として基礎的な治療薬です。その作用機序-26Sプロテアソームを選択的に阻害すること-は、悪性形質細胞のタンパク質分解経路を破壊し、アポトーシスと腫瘍抑制をもたらします。その結果、ボルテゾミブは、免疫調節剤、副腎皮質ステロイド、化学療法剤との併用レジメンにおいて、フロントラインと再発/難治性の両方で重要な役割を果たしています。多発性骨髄腫は世界的に血液がんの大部分を占めており、ボルテゾミブはその有効性、持続的な奏効率、他の標的治療薬との適合性が証明されているため、治療アルゴリズムの主軸であり続けています。

静脈内または皮下投与の注射剤であるため、投与量に柔軟性があり、患者ごとの治療計画をサポートします。より新しいプロテアソーム阻害剤やCAR-T療法の出現にもかかわらず、ボルテゾミブは、その特徴的な安全性プロファイル、確固たる臨床歴、国際的な治療ガイドラインにおける確立された位置づけにより、年齢層や病期を問わず広く処方されています。

ボルテゾミブの臨床的・商業的妥当性は、製剤の進歩と市場の拡大によってどのように維持されているのでしょうか？

ボルテゾミブの投与とスケジューリングの継続的な最適化により、忍容性が向上し、多様な患者集団での使用が拡大しています。皮下投与は、静脈内投与と比較して末梢神経障害の発生率を減少させ、患者のコンプライアンスを向上させるため、多くの地域で好ましい投与経路となっています。また、特に高齢者や虚弱な患者において、有効性と長期的な忍容性のバランスをとるため、用量調整レジメンや週1回の投与スケジュールが採用されるようになっています。

ジェネリック医薬品の参入とバイオシミラー開発により、特にコストに敏感な市場では、ボルテゾミブがより手頃な価格で入手しやすくなっています。いくつかのメーカーは、価値ベースの価格戦略を導入し、より広範な地域での販売を行うことで、低・中所得国での入手可能性を高めています。このような拡大は、骨髄腫の罹患率が高く、腫瘍学的資源に制約のある地域では特にインパクトがあり、ボルテゾミブに基づくレジメンが最もアクセスしやすく、効果的な治療選択肢となることが多いです。

ボルテゾミブの需要はどこで伸びており、どの患者層が利用を促進しているのか？

北米と欧州での需要が最も高く、ボルテゾミブはファーストラインや再発レジメンにおける標準治療薬となっています。米国と欧州では、保険償還の適用範囲と臨床的コンセンサスに支えられ、大学や地域のがん診療施設で広く採用され続けています。アジア太平洋、ラテンアメリカ、アフリカの一部では、規制当局の承認、ジェネリック医薬品の入手可能性、がん医療インフラの改善により、より幅広い市場への浸透が可能になり、需要が拡大しています。

中心的な患者層は、新規に診断された多発性骨髄腫患者（特に幹細胞移植不適格患者）、およびサルベージ療法の一環としてプロテアソーム阻害を必要とする再発/難治性患者です。VTD療法（ボルテゾミブ、サリドマイド、デキサメタゾン）やVRd療法（ボルテゾミブ、レナリドミド、デキサメタゾン）のような併用レジメンでの使用が普及しています。多発性骨髄腫の診断において大きな割合を占める高齢者人口は、リスクに応じた投与と管理可能な毒性に適合する薬剤であることから、引き続き販売量の主要な牽引役となっています。

ボルテゾミブ市場の世界的成長の原動力は？

ボルテゾミブの世界市場は、多発性骨髄腫の罹患率の継続的な上昇、エビデンスに基づく併用療法の採用拡大、費用対効果の高いジェネリック医薬品の利用可能性の増加によって牽引されています。がん治療が精密レジメンや慢性疾患管理モデルへとシフトする中、ボルテゾミブの持続的かつ相乗的な薬剤としての役割は、臨床的にも商業的にも持続的な妥当性を確保しています。主要な腫瘍学団体のガイドラインは、治療ライン全体にわたってボルテゾミブの使用を支持し続けており、血液がんプロトコールにおけるボルテゾミブの地位を強化しています。

競合品の製造、有利なコスト構造、国際的な資金提供プログラムは、特に新興経済諸国において、より広範なアクセスを支えています。プロテアソーム阻害療法が骨髄腫治療の基礎となるメカニズムであり続ける中、決定的な疑問が浮上してきました。治療パラダイムの進化、生物学的製剤との競合の激化、長期的ながん管理におけるQOLの向上という課題に適応しながらも、ボルテゾミブは戦略的治療価値と世界なアクセシビリティを維持し続けることができるだろうか。

セグメント

製品タイプ（注射剤、注射用粉末剤）、用途（多発性骨髄腫、マントル細胞リンパ腫、その他の血液悪性腫瘍）、エンドユーザー（病院、腫瘍クリニック、外来手術センター、その他のエンドユーザー）

調査対象企業の例（注目44社）

• Accord Healthcare Ltd.
• Amneal Pharmaceuticals, Inc.
• Apotex Inc.
• Bristol Myers Squibb
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Fresenius Kabi AG
• Gland Pharma Ltd.
• Hikma Pharmaceuticals PLC
• Hetero Labs Ltd.
• Johnson & Johnson
• Meitheal Pharmaceuticals, Inc.
• Mylan Pharmaceuticals Inc.
• Natco Pharma Ltd.
• Novartis International AG
• Pfizer Inc.
• Qilu Pharmaceutical Co., Ltd.
• Sandoz International GmbH
• Shilpa Medicare Ltd.
• Takeda Pharmaceutical Company Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Bortezomib Market to Reach US$28.4 Million by 2030

The global market for Bortezomib estimated at US$23.9 Million in the year 2024, is expected to reach US$28.4 Million by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Bortezomib Injection, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$18.3 Million by the end of the analysis period. Growth in the Bortezomib Powder for Injection segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.5 Million While China is Forecast to Grow at 5.4% CAGR

The Bortezomib market in the U.S. is estimated at US$6.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.5 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Bortezomib Market - Key Trends & Drivers Summarized

Why Is Bortezomib a Cornerstone in the Treatment Landscape for Hematologic Malignancies?

Bortezomib, a first-in-class proteasome inhibitor, remains a foundational therapy in the management of multiple myeloma and mantle cell lymphoma (MCL). Its mechanism of action-selectively inhibiting the 26S proteasome-disrupts protein degradation pathways in malignant plasma cells, leading to apoptosis and tumor suppression. As a result, Bortezomib plays a critical role in both frontline and relapsed/refractory settings, often in combination regimens with immunomodulators, corticosteroids, and chemotherapeutics. With multiple myeloma accounting for a significant portion of hematologic cancers globally, Bortezomib continues to be a mainstay in treatment algorithms due to its proven efficacy, durable response rates, and compatibility with other targeted therapies.

Its injectable formulation-administered either intravenously or subcutaneously-offers dosing flexibility and supports patient-specific treatment planning. Despite the advent of newer proteasome inhibitors and CAR-T therapies, Bortezomib remains widely prescribed across age groups and disease stages due to its well-characterized safety profile, robust clinical history, and established place in international treatment guidelines.

How Are Formulation Advancements and Market Expansions Sustaining Bortezomib’s Clinical and Commercial Relevance?

Ongoing optimization of Bortezomib delivery and scheduling is enhancing tolerability and expanding its use among diverse patient populations. Subcutaneous administration has become the preferred route in many regions, offering reduced incidence of peripheral neuropathy and improved patient compliance compared to intravenous delivery. Dose-adjusted regimens and weekly schedules are also being adopted to balance efficacy with long-term tolerability, especially in elderly or frail patients.

Generic entry and biosimilar development are making Bortezomib more affordable and accessible, particularly in cost-sensitive markets. Several manufacturers are introducing value-based pricing strategies and broader geographic distribution, increasing availability in lower- and middle-income countries. This expansion is particularly impactful in regions with high myeloma burden and constrained oncology resources, where Bortezomib-based regimens often represent the most accessible and effective treatment option.

Where Is Demand for Bortezomib Growing and Which Patient Segments Are Driving Utilization?

Demand remains highest in North America and Europe, where Bortezomib is a standard-of-care component in first-line and relapse regimens. The U.S. and EU markets continue to see widespread adoption across academic and community oncology practices, supported by reimbursement coverage and strong clinical consensus. In Asia-Pacific, Latin America, and parts of Africa, demand is expanding as regulatory approvals, generic availability, and oncology infrastructure improvements enable broader market penetration.

Core patient segments include newly diagnosed multiple myeloma patients-particularly those ineligible for stem cell transplantation-as well as relapsed/refractory cases requiring proteasome inhibition as part of salvage therapy. Use in combination regimens such as VTD (Bortezomib, thalidomide, dexamethasone) or VRd (Bortezomib, lenalidomide, dexamethasone) is widespread. The elderly population, which comprises a large proportion of multiple myeloma diagnoses, continues to be a key driver of volume due to the drug’s compatibility with risk-adapted dosing and manageable toxicity.

What Is Fueling the Global Growth of the Bortezomib Market?

The global Bortezomib market is being driven by the continued rise in multiple myeloma incidence, expanding adoption of evidence-based combination therapies, and the increasing availability of cost-effective generics. As oncology treatment shifts toward precision regimens and chronic disease management models, Bortezomib's role as a durable and synergistic agent is ensuring sustained clinical and commercial relevance. Guidelines from major oncology bodies continue to support its use across lines of therapy, reinforcing its embedded status in hematologic cancer protocols.

Competitive manufacturing, favorable cost structures, and international donor programs are supporting broader access, particularly in emerging economies. As proteasome inhibition remains a cornerstone mechanism in myeloma care, a defining question emerges: Can Bortezomib continue to retain strategic therapeutic value and global accessibility-while adapting to evolving treatment paradigms, rising biologic competition, and the push for improved quality of life in long-term cancer management?

SCOPE OF STUDY:

The report analyzes the Bortezomib market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Injection, Powder for Injection); Application (Multiple Myeloma, Mantle Cell Lymphoma, Other Hematological Malignancies); End-User (Hospitals, Oncology Clinics, Ambulatory Surgery Centers, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Accord Healthcare Ltd.
• Amneal Pharmaceuticals, Inc.
• Apotex Inc.
• Bristol Myers Squibb
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Fresenius Kabi AG
• Gland Pharma Ltd.
• Hikma Pharmaceuticals PLC
• Hetero Labs Ltd.
• Johnson & Johnson
• Meitheal Pharmaceuticals, Inc.
• Mylan Pharmaceuticals Inc.
• Natco Pharma Ltd.
• Novartis International AG
• Pfizer Inc.
• Qilu Pharmaceutical Co., Ltd.
• Sandoz International GmbH
• Shilpa Medicare Ltd.
• Takeda Pharmaceutical Company Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Bortezomib - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Multiple Myeloma Incidence Underpins Sustained Demand for Bortezomib Therapies
  • Inclusion in First-Line and Relapsed/Refractory Regimens Reinforces Clinical Importance of Bortezomib
  • Subcutaneous Formulations Improve Patient Tolerability and Administration Efficiency
  • Biosimilar Approvals Expand Access and Reduce Treatment Costs Across Emerging Markets
  • Combination Therapy With Immunomodulators and Steroids Enhances Overall Treatment Response
  • Real-World Evidence Supports Continued Use of Bortezomib in Elderly and High-Risk Patients
  • New Indications in Mantle Cell Lymphoma Broaden Market Beyond Multiple Myeloma
  • Manufacturer Focus on Cold Chain Stability and Ease-of-Mixing Packaging Improves Adoption
  • Resistance Management Strategies Reinforce Bortezomibs Role in Treatment Sequencing
  • Global Cancer Protocols and NCCN Guidelines Sustain Bortezomib as a Market Staple
  • Expanded Use in Maintenance Therapy and Triplet Regimens Drives Volume in Hematologic Oncology
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Bortezomib Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Bortezomib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Powder for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Powder for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Powder for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Multiple Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Mantle Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Hematological Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Hematological Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Hematological Malignancies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Oncology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Oncology Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Oncology Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• JAPAN
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• CHINA
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• EUROPE
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Bortezomib by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• FRANCE
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• GERMANY
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Bortezomib by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• INDIA
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Bortezomib by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Bortezomib by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Bortezomib by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Bortezomib by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030
• AFRICA
  • Bortezomib Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Bortezomib by Product Type - Injection and Powder for Injection - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Bortezomib by Product Type - Injection and Powder for Injection Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Bortezomib by Product Type - Percentage Breakdown of Value Sales for Injection and Powder for Injection for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Bortezomib by Application - Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Bortezomib by Application - Percentage Breakdown of Value Sales for Multiple Myeloma, Mantle Cell Lymphoma and Other Hematological Malignancies for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Bortezomib by End-user - Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Bortezomib by End-user - Percentage Breakdown of Value Sales for Hospitals, Oncology Clinics, Ambulatory Surgery Centers and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION